Trevena, Inc. (NASDAQ:TRVN) was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania, USA. It has 28 full-time employees. It is a biopharmaceutical company dedicated to the development of breakthrough science-based treatments to enable patients with serious diseases And medical service providers benefit.
Trevena, Inc. (TRVN):
Trevena Inc is a clinical-stage biopharmaceutical company headquartered in Chesterbrook, Pennsylvania, USA, involved in the discovery and development of G protein-coupled receptor biased ligands. Trevena was founded in 2007 with technology licensed from Duke University. The founders of the company are Howard Rockman and Robert Lefkowitz, the latter being the 2012 Nobel Prize in Chemistry.
Trevena’s drug discovery method is based on the use of ligand bias or functional selectivity on GPCR targets to produce drugs with improved efficacy and reduced side effects characteristics. Trevena was named one of the top 15 American startups in 2008 by Business Week.
Trevena’s expertise lies in the design of “biased ligands” that only activate beneficial signaling pathways downstream of GPCRs to unlock new biology and avoid adverse drug reactions. Trevena’s pipeline currently includes clinical-stage μ-opioid-biased ligands for postoperative pain, as well as discovery-stage programs for chronic pain, migraine, and Parkinson’s disease.
Trevena product candidates include:
- OLINVO injection, the G protein biased ligand of the μ opioid receptor, has completed phase III clinical trials for the treatment of moderate to severe acute pain, and intravenous administration is preferred
- TRV250, a G protein biased ligand targeting d receptors, used in a phase I clinical study for the treatment of migraine
- TRV734, a small molecule G protein biased ligand for μ opioid receptors, has completed phase I clinical research for the treatment of moderate to severe acute and chronic pain
- TRV027, used to treat acute heart failure
Trevena, Inc. (TRVN) History:
- In 2008, the company raised US$25 million in Series A financing, mainly from Alta Partners, Polaris Ventures, New Enterprise Associates, Healthcare Ventures and Yasuda Economic Development Corporation.
- In early 2009, Trevena and Ligand Pharmaceuticals reached a cooperation agreement to identify biased ligands among the numerous GPCRs from a large and diverse library.
- In late 2009, Trevena received the American Recovery and Reinvestment Act Grand Opportunities Grant, which lasted for two years and funded $7.65 million in research funding.
- The company raised another $35 million in Series B venture financing in the summer of 2010.
- In 2011, Treveva received another NIH grant as part of the NIH Blueprint Neural Therapy Network, which may be worth up to 10 million US dollars to support the preclinical development of delta opioid receptor biased ligands for major depression.
- Trevena received funding from the Michael J. Fox Foundation to explore the potential of delta opioid receptor biased ligands for the treatment of Parkinson’s disease.
- On January 30, 2014, Treveva IPO landed on Nasdaq.